Acquired Fanconi Syndrome After Treatment with Capecitabine, Irinotecan, and Bevacizumab

Author:

Shaikh Aisha1,Wiisanen Matthew E2,Gunderson Heidi D3,Leung Nelson4

Affiliation:

1. Attending Physician, Wichita Nephrology Group, Wichita, KS

2. Division of Cardiovascular Diseases, Gill Heart Institute, University of Kentucky, Lexington, KY

3. Hematology/Oncology Disease Management, Mayo Clinic, Rochester, MN

4. Medicine, Consultant in the Division of Nephrology and Hypertension, Mayo Clinic Rochester, Rochester

Abstract

Objective: To describe a case of acquired Fanconi syndrome after treatment with capecitabine, irinotecan, and bevacizumab. Case Summary: A 77-year-old female with metastatic colon cancer presented with vomiting and diarrhea. The patient had been diagnosed with stage IIIC (T3, N2, M0) colon cancer 18 months earlier and was initially treated with FOLFOX6 (regimen of oxaliplatin, fluorouracil, and leucovorin) after her hemicolectomy. She was switched to a capecitabine/oxaliplatin regimen after 4 cycles due to central access problems. She did well until 10 months after her cancer diagnosis, when metastasis was discovered. She was started on reduced doses of capecitabine, irinotecan, and bevacizumab. After her eleventh cycle, she presented to the hospital with the above symptoms. Laboratory test results showed hypokalemia, hypocalcemia, hypophosphatemia, and hypouricemia. The patient had not been started on any new medications other than chemotherapy for over 1 year. The electrolyte derangements were new, since the patient had laboratory values checked every 3 weeks. Despite daily intravenous replacements, the electrolyte abnormalities persisted. Laboratory evaluations demonstrated the presence of euglycemic glucosuria and a high fractional excretion of phosphorus in the setting of hypophosphatemia. Fanconi syndrome was confirmed by demonstration of aminoaciduria. Discussion: Fanconi syndrome is a disorder characterized by proximal tubular dysfunction resulting in electrolyte wasting. In the acquired form, medications and multiple myeloma are the most common causes. Based on the Naranjo probability scale, a drug was the probable cause of Fanconi syndrome in our patient. However, because multiple drugs were involved, it was not possible to determine which one was the culprit. Conclusions: This is the first case of Fanconi syndrome reported after the administration of capecitabine, irinotecan, and bevacizumab. More studies are needed to confirm this association.

Publisher

SAGE Publications

Subject

Pharmacology (medical)

Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Valproic acid as an adjuvant analgesic: adult Fanconi syndrome;BMJ Supportive & Palliative Care;2022-06-28

2. Drug-induced hypophosphatemia;Medical alphabet;2021-10-02

3. Hypophosphatemia in cancer patients;Clinical Kidney Journal;2021-04-15

4. Electrolyte Disorders Induced by Antineoplastic Drugs;Frontiers in Oncology;2020-05-19

5. Transient Fanconi Syndrome After Treatment with Firocoxib, Cefadroxil, Tramadol, and Famotidine in a Maltese;Journal of the American Animal Hospital Association;2019-11-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3